NCT02171728View on ClinicalTrials.gov

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

September 30, 2006

Conditions
Neoplasms
Interventions
DRUG

BIBW 2992

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02171728 - Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter